BTG Live Discussion

stout-hart 06 Jun 2018

Re: Shar,e Price re Andy Burrows repl Doesn't sound like an unreasonable response to me. SP movements sometimes happen with no apparent correlation to any facts. Part of the irrationality of markets I suppose.

up protherics 06 Jun 2018

Re: Shar,e Price re Andy Burrows repl Thanks for sharing the e-mail pauloverdi..So what he is saying is that BTG believe crofab is superior.. How arrogant wouldn't it be nice if the board re assured the market. We can only live in hope, but as I mentioned before they seem to be inept of late.What I find really worrying is that the so called analyst,s which promoted this stock have very little to say on the matter.INMO someone is lying somewhere along the line.All positive from half a dozen brokers and the price does nothing , but declines. Then a negative broker note from one and the price collapses.. I wouldn't be surprised if this has been orchanstrated to facilitate a takeover.. Lets all hope so.. I would definatly settle for £7.00 now just to be rid of this..A bid came in from nowhere for shire so we may get lucky now

pauloverdi 06 Jun 2018

Shar,e Price re Andy Burrows repl Contacted Andy Burrows re the tanking of the share price and, as usual, nothing stated by the board !! I find this unacceptable but has always been this way. The board seem to have little regard for us shareholder !!! Anyway here is his response emailed to me just now,Hi Paul,It is very frustrating, I know. Late yesterday an analyst published a note downgrading us to an Underperform, based on his assessment that the market is not baking in sufficient for CroFab competition (a product from a Mexican company can launch in the US from October 20918). He is basing his assessment on claimed superiority of that product in something called "recurrent coagulopathy"; however, their small study that resulted in approval failed to meet its primary endpoint of demonstrating superiority to CroFab in that regard. I expect there to be support for the shares, but in these markets investors tend to wait to see how low they can buy for...Regards,AndyAndy BurrowsVice President, Corporate and Investor Relations.BTG plc

up protherics 06 Jun 2018

Any Views Does anyone have any views on the latest here.. I know RBC downgraded this to £5.00.If the fall is down to that it does not say much for the rest of the so called analysts who have constantly backed this does it.As company they really do need to come up with something positive as all they seem able to do is throw away millions of late.I would not be surprised if there is some sort of Iranian connection somew

shugg1e 05 Jun 2018

Re: nice drop £3 would be great a gift but i doubt it will get thereFingers crossed though you never know

up protherics 05 Jun 2018

nice drop I see this basket case of a pantomime continues in decimating shareholder value.There is not even any interest from third parties in acquiring this. Who can blame them.My guess is that even the institutions have had enough.Still I suppose if it hits three pounds someone my take a look.

Mike Land 16 May 2018

Re: Andy Burrows response A broadly fair response but does not explain the market response to the results. I think he is wrong to say AZ and Glaxo report in $ - ie UK businesses do not report in $ but as most quoted businesses report in $ because they are US businesses. I think it is the cumulative effect of the stupid management mistakes on the two big charges allied to a feeling that growth has gone from current products and therefore relying on more acquisitions yet this is where they have shown they have made big mistakes in recent deals. And their hedging has resulted in very odd losses so this will mean the FD cannot be caught out in future!Could be they want to show better $ results for the eventual sale?? They will have already changed their results looking back to show to buyers.

pauloverdi 16 May 2018

Andy Burrows response I contacted Andy re our serious concerns. He replied back to me yesterday.Hi Paul,Thanks for your email. Quite a strong SP reaction as you say, partly the analysts who didn't update after the April close period taking their revenues out for PneumRx for the next couple of years.There is no rule about reporting currency, and actually it's very common in the healthcare industries to report in dollars. We are doing it because about 90% of current revenues are in dollars as you note and ~55% of costs, so we will take a lot of volatility out of our results as a result of foreign exchange translation effects. We have had a hedging policy to cover our future dollar cash flows, and by and large when you have seen losses on forward contracts you have seen roughly an equal gain on translation benefits - and vice versa.There is no ulterior motive than reducing volatility in the results and using the common currency in healthcare. However, in my role I also see it as an opportunity to make us a bit friendlier to US-based investors, and would love to attract more of them. There are actually quite a few precedents of £ reporters converting, but that's not why we are doing it - it's for the above reasons. Every analyst I have spoken with has said it's a very sensible move, as have the institutional investors we have talked to about it.You are absolutely right that we want to make our business more global...it's about where we started from. CroFab is a US-only product of course, and most of the companies we have bought have been VC-backed US-based businesses who focused strongly on their home market. So we have been investing in a number of things to lay the foundations for ex-US growth: setting up appropriate levels of commercial infrastructure in other areas such as EU and Asia, including some direct sales presence and an expanded distributor network. We have also been going through the necessary but time-consuming process of registering our products in the various territories. Then we have been planning our marketing etc. So it doesn't show in the result yet, but within a few years we should start to see a greater contribution from the EU and other geographies.Kind regards,AndyAndy BurrowsVice President, Corporate and Investor Relations.BTG plc

d gaser 15 May 2018

Re: accounts to change from pounds to US... Further to my last post regarding BTG, regarding the change of currency to US Dollars for sales and reporting , it appears that the Dollar is more unstable than the pound right now .That might have some thing to do with Mr Trump threating everybody, but saying that, had you brought the dollar on the first of Jan 2018 you would have got 1.3513 U.S.D to the pound, and today, there is little change as the exchange rate on the 14 May was 1.3561U.S.D to the pound .However over the last two years, the dollar has fluctuated against the pound a lot , from 1.471-U.S.D to the pound to 1.35 -U.S.D, so why change over now? When the BOD say they want to increase trade with Europe and the rest of the world? where the dollor fluctuates even more www.exchangerates.org.uk/GBP-USD-exchange-rate-history.htmlBE HAPPYDav

up protherics 15 May 2018

Re: accounts to change from pounds to US... Havent you herd America now rules the world.. Whatever they say goes.. Knowing how this mob works ( because that is what they are) the rump organisation is now demanding that any company carrying out u.s business must hold their cash in USD.Hopefully there is a nice up for sale on this . I will settle for £8.00 for whats left of my sha

Mike Land 15 May 2018

Re: accounts to change from pounds to US Dol... If accounts are in dollars and we keep our spare cash in dollars then we will not have to account for any sales exchange losses or gains but obviously the costs are mostly in £ and Aussie dollars so there will be an effect there! As there is no dividend the eps is affected when you convert the rate but that in itself is odd.Results not good despite the underlying sales strength as the royalty receipts are about to reverse. I should have sold this years cgt free amount for this tax year before this!! Now I will have to wait for the market to settle recover.

d gaser 15 May 2018

accounts to change from pounds to US Dollar why ? I always thought a company had to report it's financial accounts in the currency of the country where it is registered and where it's head office is situated, yet here ,we have Louise saying that our accounts in future will be using the US dollar ,is she trying to tell us some thing ?.This statement also comes when they are saying they want to extend BTG reach across the world ,which is some thing I have wanted for several years as I just can't understand why a company like ours ,has 90 % of it's sales in the USA, and only 7% in Europe, which is our nearest, and at present our only free market ,leaving just 3% for the rest of the world. We all know BTG has not been good at laying of currency over the past few years , and have lost millions by being on the wrong side of the up and downs of the dollar , and that wont change if we use the dollar, instead of the pound ,especially, as they say they want to increase sales to Europe and the rest of the world ,so why change from the pound to dollar now ?So I ask my self Have the BOD got an alternative motive for this change?Answers please ,as I have not held stock in another UK company where this change has occurred.Thanks be happy Dav

autpaxautbellum 15 May 2018

Re: Results Yes, from a low base.Put the whole shooting match up for sale and have a clean break!

dave297 15 May 2018

Results At least Varithena showed strong growth -jewel in our crown ?

pauloverdi 30 Apr 2018

OPTALYSE RE BTG OPTALYSE PE Results Presented at Society for Cardiovascular Angiography and InterventionsBusiness Wire Business WireApril 27, 2018BOTHELL, Wash.--(BUSINESS WIRE)--BTG plc (BTG.L), the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with significantly less tissue plasminogen activator (tPA) than used in previous studies1- as low as 8mg total - show significant improvement in RV/LV ratio over both the short and long term and with a very low mortality rate of 2% and an equally low recurrent PE rate of 2%.“EKOS is the only endovascular device cleared by the FDA for the treatment of pulmonary embolism,” said Dr. Gregory Piazza, Cardiologist for Brigham and Women’s Hospital and professor at Harvard Medical School. “We are constantly in need of more data to help drive decision-making in PE. So far the most data that exists in PE is associated with EKOS therapy and the data provided in the OPTALYSE study advances the science of PE treatment even further.”The one-year data from OPTALYSE PE demonstrates improved quality of life of over 30% using two unique measurement systems. ”Prior to this data being published, comparable studies put one-year mortality at 8-10% when treating with systemic thrombolysis or anti-coagulation2,” explained Lynn Allen, Vice President of Clinical Affairs for BTG Vascular. “This one-year data further demonstrates the safety – with only 3% bleeding, proven quality and effectiveness of the OPTALYSE PE treatment regimens and now we can also demonstrate quality of life improvement for these patients.”A separate registry study, KNOCOUT PE is intended to measure how institutions are adopting OPTALYSE PE and this new standard of care. The study is expected to include as many as 100 centers globally and is currently enrolling.About the EkoSonic® Endovascular SystemThe EKOS® system uses ultrasonic waves in combination with clot-dissolving thrombolytic drugs to effectively dissolve clots and restore healthy heart function and blood flow.In clinical studies, EKOS® therapy has been shown to speed time-to-clot dissolution, increase clot removal and enhance clinical improvement compared to either standard catheter-directed drug therapy or thrombectomy. EKOS® therapy requires significantly shorter treatment times and less thrombolytic compared to standard catheter-directed drug therapy, lowering the risk of bleeding and other complications.About the OPTALYSE PE, ULTIMA and SEATTLE II studiesThe OPTALYSE PE, ULTIMA and SEATTLE II studies prospective multi-center trials examining ultrasound-facilitated, catheter-directed thrombolysis using a low dose of a standard clot dissolving medication called tissue plasminogen activator (tPA) to treat both acute massive and submassive pulmonary embolism.ULTIMA, a randomized controlled study comparing EKOS® therapy to anticoagulation, looked at 59 patients across eight centers and proved that the EKOS® regiment was superior to anticoagulation alone.SEATTLE II, a prospective single arm study, looked at 150 patients across 22 centers and demonstrated improvement in RV/LV ratio, pulmonary hypertension and angiographic obstruction with EKOS® therapy.OPTALYSE PE included 101 patients with acute proximal PE at 17 centers randomized to one of four treatment cohorts – with cohorts ranging between 2-6 hours in treatment duration and from 4-6mg/tpA total per device. All cohorts saw a significant reduction in the main indicator of right heart strain from PE (measured as right ventricular to left ventricular diameter ratio (RV/LV)) by approximately 23 to 26 percent. The OPTALYSE PE results also showed a very low bleeding rate of three percent. Beyond the acute results, echocardiograms were provided at four hours, 48 hours, 30 day